Şunu aradınız:: thienopyridine (İngilizce - Maltaca)

use of any thienopyridine within 5 days before enrolment was an exclusion criterion.
l- użu ta 'xi thienopyridine fi żmien 5 ijiem qabel ir- reġistrazzjoni kien kriterju ta' esklużjoni.

93.2 % of patients received asa concomitantly plus thienopyridine treatment and 6.8 % asa only.
93.2 % tal-pazjenti rċevew asa fl-istess waqt flimkien ma’ kura b’thienopyridine u 6.8 % irċevew asa biss.

§ cox proportional hazard model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use)
§ mudell ta’ periklu proporzjonali cox b’kovarjati ta’ fatturi ta’ trattament u stratifikazzjoni (mard aterosklerotiku li jikkwalifika u użu ppjanat ta’ thienopyridine)

patients who had developed a previous allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
pazjenti li qabel żviluppaw reazzjoni allerġika u/jew reazzjoni ematoloġika għal thienopyridine jista’ jkollhom żieda fir-riskju li jiżviluppaw l-istess reazzjoni jew reazzjoni oħra għal thienopyridine ieħor.

patients who had developed a previous monitored allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
pazjenti li qabel żviluppaw reazzjoni allerġika u/jew reazzjoni ematoloġika għal thienopyridine jista’ jkollhom żieda fir-riskju li jiżviluppaw l-istess reazzjoni jew reazzjoni oħra għal thienopyridine ieħor.

monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised.
huwa rrakkomandat li jsir monitoraġġ għal sinjali ta’ sensittività eċċessiva f’pazjenti magħrufa li għandhom allerġija għal thienopyridine